Want to see SE:LXB full AI Analyst Report?
Top Page
Luxbright AB
(LXB)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr0.05
▼(-90.21% Downside)
Action:Reiterated
Date:09/08/26
The score is held down primarily by weak financial performance—ongoing heavy losses, unstable margins, and persistent cash burn—despite a low-debt balance sheet. Technicals add additional pressure with a strong downtrend and bearish momentum. Valuation provides limited support because negative earnings make the P/E less meaningful and no dividend yield is available.
Positive Factors
Low leverage and equity cushion
Minimal debt reduces financial risk and interest-related pressure, while sizable equity provides a cushion against operating volatility. This balance-sheet position can preserve strategic flexibility and help the company fund development or commercialization efforts while it works toward profitability.
Negative Factors
Persistent operating losses
Persistent net losses and deeply negative operating results show that the business has not yet converted its technology and revenue activity into sustainable earnings. Continued losses can erode the equity base over time and constrain the company’s ability to invest without additional financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and equity cushion
Minimal debt reduces financial risk and interest-related pressure, while sizable equity provides a cushion against operating volatility. This balance-sheet position can preserve strategic flexibility and help the company fund development or commercialization efforts while it works toward profitability.
Read all positive factors
Luxbright AB (LXB) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr13.08M
Dividend YieldN/A
Average Volume (3M)554.64K
Price to Earnings (P/E)―
Beta (1Y)-0.59
Revenue Growth-13.46%
EPS Growth4.75%
CountrySE
Employees11
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.16
Shares Outstanding242,242,220
10 Day Avg. Volume1,144,192
30 Day Avg. Volume554,638
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)2.09
Price to Sales (P/S)4.94
P/FCF Ratio-2.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr17.50M
Luxbright AB Business Overview & Revenue Model
Company Description
Luxbright AB (publ), a technology-driven enterprise headquartered in Gothenburg, Sweden, specializes in engineering and marketing X-ray tubes, generators, and comprehensive X-ray systems. Established in 2012, the company's primary focus is on prov...
How the Company Makes Money
Luxbright AB’s revenue model is based on monetizing its X-ray source technology through sales and commercialization of products and related offerings. The primary revenue stream is expected to be direct revenue from delivering X-ray sources and/or...
Luxbright AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.35M | 11.41M | 9.02M | 854.70K | 811.70K | 729.00K |
| Gross Profit | -38.22M | -21.37M | 8.88M | -2.80M | 189.12K | 1.98M |
| EBITDA | -19.23M | -16.76M | -15.72M | -23.87M | -20.47M | -17.63M |
| Net Income | -21.51M | -19.46M | -17.72M | -25.38M | -21.13M | -18.10M |
Balance Sheet | ||||||
| Total Assets | 32.25M | 39.38M | 42.66M | 40.69M | 31.19M | 23.99M |
| Cash, Cash Equivalents and Short-Term Investments | 362.00K | 5.29M | 12.36M | 14.04M | 7.60M | 7.51M |
| Total Debt | 3.24M | 4.56M | 254.19K | 206.02K | 588.34K | 1.10M |
| Total Liabilities | 8.85M | 12.49M | 8.46M | 7.00M | 3.33M | 3.36M |
| Stockholders Equity | 23.41M | 26.89M | 34.20M | 33.69M | 27.86M | 20.63M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -19.87M | -16.52M | -20.39M | -20.64M | -17.14M |
| Operating Cash Flow | -20.93M | -19.87M | -16.52M | -20.39M | -20.64M | -17.14M |
| Investing Cash Flow | -2.92M | -3.65M | -3.44M | -3.99M | -7.15M | -4.15M |
| Financing Cash Flow | 7.89M | 16.46M | 18.28M | 30.82M | 27.88M | -708.00K |
Luxbright AB Technical Analysis
Negative
0.48
Price Trends
0.09
Negative
0.12
Negative
0.27
Negative
Market Momentum
-0.01
Positive
37.12
Neutral
23.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LXB, the sentiment is Negative. The current price of 0.48 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.09, and above the 200-day MA of 0.27, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 37.12 is Neutral, neither overbought nor oversold. The STOCH value of 23.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:LXB.
Luxbright AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | kr1.35B | -265.81 | -1.22% | ― | 34.05% | -144.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr560.70M | -66.67 | -2.84% | ― | -13.72% | 52.47% | |
46 Neutral | kr49.60M | -14.43 | ― | ― | -12.32% | -1156.14% | |
42 Neutral | kr13.08M | -0.34 | -85.54% | ― | -13.46% | 4.75% | |
42 Neutral | kr192.75M | -1.18 | -303.61% | ― | 51.21% | 42.24% | |
41 Neutral | kr40.57M | -0.19 | -57.15% | ― | ― | 16.02% |
* Healthcare Sector Average
SE:LXB
Luxbright AB
0.05
-0.62
-92.71%
SE:PAX
Paxman AB
58.50
-20.10
-25.57%
SE:SCIB
SciBase Holding AB
18.50
-8.67
-31.90%
SE:SPEC
SpectraCure AB
0.02
-0.11
-83.08%
SE:BACTI.B
Bactiguard Holding AB
16.10
-9.50
-37.11%
SE:SDOS
ScandiDos AB
0.87
-0.39
-30.95%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.